SCHEMBL20232152

SCHEMBL20232152

CC(C)c1ccc(Cl)c(OCCCCCCS(=O)(=O)O)c1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.41
KDM4E B2RXH2 3/20 0.41
LMNA P02545 3/20 0.40
SMN1; SMN2 Q16637 3/20 0.40
MAPT P10636 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
BCHE P06276 3/20 0.39
ACHE P22303 3/20 0.39
PDE5A O76074 1/20 0.37
PDE1A P54750 1/20 0.37
PDE1B Q01064 1/20 0.37
PDE4D Q08499 1/20 0.37
PDE7A Q13946 1/20 0.37
PDE1C Q14123 1/20 0.37
PDE3A Q14432 1/20 0.37
NPSR1 Q6W5P4 1/20 0.36
MEN1 O00255 1/20 0.36
NPC1 O15118 1/20 0.36
RAB9A P51151 1/20 0.36
KMT2A Q03164 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20232157 0.90 NPSR1 (0.44) ALDH1A1KDM4ELMNASMN1; SMN2MAPT
SCHEMBL20232151 0.90 NPSR1 (0.44) ALDH1A1KDM4ELMNASMN1; SMN2MAPT
SCHEMBL20216134 0.82 ALDH1A1 (0.41) ALDH1A1KDM4ELMNASMN1; SMN2MAPT
SCHEMBL13321621 0.82 ALDH1A1 (0.51) ALDH1A1KDM4ELMNASMN1; SMN2MAPT
SCHEMBL20232156 0.82 MRGPRX4 (0.42) ALDH1A1LMNASMN1; SMN2L3MBTL1BCHE
SCHEMBL13321620 0.80 ALDH1A1 (0.52) ALDH1A1KDM4ELMNASMN1; SMN2MAPT
SCHEMBL20225815 0.80 ALDH1A1 (0.44) ALDH1A1KDM4ELMNASMN1; SMN2MAPT
SCHEMBL16939767 0.79 ALDH1A1 (0.45) ALDH1A1KDM4ELMNASMN1; SMN2MAPT
SCHEMBL20225802 0.77 PPARG (0.41) ALDH1A1KDM4ELMNASMN1; SMN2MAPT
SCHEMBL20225820 0.77 PPARG (0.41) ALDH1A1KDM4ELMNASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11192894-B2 Cell impermeable coelenterazine analogues PROMEGA CORPORATION (US) 2021-12-07 US disclosed
US-20200239475-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES PROMEGA CORPORATION 2020-07-30 US disclosed
US-10577370-B2 Cell impermeable coelenterazine analogues PROMEGA CORPORATION (US) 2020-03-03 US disclosed
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES JPMORGAN CHASE BANK, N.A., AS COLLATERAL AGENT 2018-06-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11192894-B2 Cell impermeable coelenterazine analogues SI, GLB1, MRPL21 ALDH1A1 3715/4885KDM4E 3481/4885LMNA 1636/4885
US-10577370-B2 Cell impermeable coelenterazine analogues SI, GLB1, MRPL21 ALDH1A1 3715/4885KDM4E 3481/4885LMNA 1636/4885
US-20200239475-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES SI, GLB1, MRPL21 ALDH1A1 3715/4885KDM4E 3481/4885LMNA 1636/4885
US-20180155350-A1 CELL IMPERMEABLE COELENTERAZINE ANALOGUES SI, GLB1, MRPL21 ALDH1A1 3715/4885KDM4E 3481/4885LMNA 1636/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.